Literature DB >> 20880505

Astrocytes and therapeutics for Parkinson's disease.

Phillip M Rappold1, Kim Tieu.   

Abstract

Astrocytes play direct, active, and critical roles in mediating neuronal survival and function in various neurodegenerative disorders. This role of astrocytes is well illustrated in amyotrophic lateral sclerosis (ALS), in which the removal of glutamate from the extracellular space by astrocytes confers neuroprotection, whereas astrocytic release of soluble toxic molecules promotes neurodegeneration. In recent years, this context-dependent dual role of astrocytes has also been documented in experimental models of Parkinson's disease. The present review addresses these studies and some potential mechanisms by which astrocytes may influence the neurodegenerative processes in Parkinson's disease, and in particular examines how astrocytes confer neuroprotection either through the removal of toxic molecules from the extracellular space or through the release of trophic factors and antioxidant molecules. In contrast, under pathological conditions, astrocytes release proinflammatory cytokines and other toxic molecules that are detrimental to dopaminergic neurons. These emerging roles of astrocytes in the pathogenesis of Parkinson's disease constitute an exciting development with promising novel therapeutic targets.
Copyright © 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880505      PMCID: PMC2948546          DOI: 10.1016/j.nurt.2010.07.001

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  123 in total

Review 1.  The Nrf2-ARE cytoprotective pathway in astrocytes.

Authors:  Marcelo R Vargas; Jeffrey A Johnson
Journal:  Expert Rev Mol Med       Date:  2009-06-03       Impact factor: 5.600

2.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

3.  Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.

Authors:  Robert A Hauser; Kelly E Lyons; Terry McClain; Summer Carter; David Perlmutter
Journal:  Mov Disord       Date:  2009-05-15       Impact factor: 10.338

4.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

Review 5.  Adenosine signaling and function in glial cells.

Authors:  D Boison; J-F Chen; B B Fredholm
Journal:  Cell Death Differ       Date:  2009-09-18       Impact factor: 15.828

6.  The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

Authors:  Chadwick W Christine; J William Langston; Robert S Turner; Philip A Starr
Journal:  J Neurosurg       Date:  2009-02       Impact factor: 5.115

7.  Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat.

Authors:  R Kannan; J F Kuhlenkamp; E Jeandidier; H Trinh; M Ookhtens; N Kaplowitz
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 8.  The genetics of Parkinson's syndromes: a critical review.

Authors:  John Hardy; Patrick Lewis; Tamas Revesz; Andrew Lees; Coro Paisan-Ruiz
Journal:  Curr Opin Genet Dev       Date:  2009-05-04       Impact factor: 5.578

9.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more
  83 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

Review 2.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

3.  Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.

Authors:  Nicolas Giguère; Consiglia Pacelli; Caroline Saumure; Marie-Josée Bourque; Diana Matheoud; Daniel Levesque; Ruth S Slack; David S Park; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

Review 4.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

Review 5.  Deep brain stimulation: are astrocytes a key driver behind the scene?

Authors:  Albert J Fenoy; Laurent Goetz; Stéphan Chabardès; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2014-01-24       Impact factor: 5.243

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

7.  Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Authors:  Matthew Neal; Jie Luo; Dilshan S Harischandra; Richard Gordon; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Laurent Désaubry; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Glia       Date:  2018-09-12       Impact factor: 7.452

Review 8.  Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect.

Authors:  Wei Cai; Kai Zhang; Peiying Li; Ling Zhu; Jing Xu; Boyu Yang; Xiaoming Hu; Zhengqi Lu; Jun Chen
Journal:  Ageing Res Rev       Date:  2016-09-30       Impact factor: 10.895

9.  TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.

Authors:  Jin H Nam; Eun S Park; So-Yoon Won; Yu A Lee; Kyoung I Kim; Jae Y Jeong; Jeong Y Baek; Eun J Cho; Minyoung Jin; Young C Chung; Byoung D Lee; Sung Hyun Kim; Eung-Gook Kim; Kyunghee Byun; Bonghee Lee; Dong Ho Woo; C Justin Lee; Sang R Kim; Eugene Bok; Yoon-Seong Kim; Tae-Beom Ahn; Hyuk Wan Ko; Saurav Brahmachari; Olga Pletinkova; Juan C Troconso; Valina L Dawson; Ted M Dawson; Byung K Jin
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

Review 10.  Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration.

Authors:  Matthew Neal; Jason R Richardson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-11-04       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.